Intracellular calcium changes induced by the endozepine triakontatetraneuropeptide in human polymorphonuclear leukocytes: role of protein kinase C and effect of calcium channel blockers
© Marino et al; licensee BioMed Central Ltd. 2004
Received: 24 January 2004
Accepted: 30 June 2004
Published: 30 June 2004
The endozepine triakontatetraneuropeptide (TTN) induces intracellular calcium ([Ca++]i) changes followed by activation in human polymorphonuclear leukocytes (PMNs). The present study was undertaken to investigate the role of protein kinase (PK) C in the modulation of the response to TTN by human PMNs, and to examine the pharmacology of TTN-induced Ca++ entry through the plasma membrane of these cells.
The PKC activator 12-O-tetradecanoylphorbol-13-acetate (PMA) concentration-dependently inhibited TTN-induced [Ca++]i rise, and this effect was reverted by the PKC inhibitors rottlerin (partially) and Ro 32-0432 (completely). PMA also inhibited TTN-induced IL-8 mRNA expression. In the absence of PMA, however, rottlerin (but not Ro 32-0432) per se partially inhibited TTN-induced [Ca++]i rise. The response of [Ca++]i to TTN was also sensitive to mibefradil and flunarizine (T-type Ca++-channel blockers), but not to nifedipine, verapamil (L-type) or ω-conotoxin GVIA (N-type). In agreement with this observation, PCR analysis showed the expression in human PMNs of the mRNA for all the α1 subunits of T-type Ca++ channels (namely, α1G, α1H, and α1I).
In human PMNs TTN activates PKC-modulated pathways leading to Ca++ entry possibly through T-type Ca++ channels.
Keywordspolymorphonuclear leukocytes triakontatetraneuropeptide intracellular Ca++ interleukin-8 protein kinase C Ca++ channel blockers T-type Ca++-channels.
Triakontatetraneuropeptide [diazepam-binding inhibitor (DBI) 17–50, TTN] is one of the major endogenous peptides generated through the cleavege of DBI, a neuropeptide also known as acyl-CoA-binding protein . DBI and DBI-derived peptides are also called endozepines, after the ability of at least some of them to recognize the diazepam binding site on the GABAA receptor, and are widely distributed in the CNS and in peripheral organs [2, 3]. In particular, immune tissues express DBI  and evidence exists that TTN and its related peptides octadecaneuropeptide (DBI 33–50, ODN) and eiksoneuropeptide (DBI 51–70, ENP) can affect the immune response. In particular, TTN and ODN stimulate the production of tumor necrosis factor (TNF) alpha, interleukin (IL)-1 beta, IL-8, granulocyte/macrophage colony-stimulating factor, IL-6 and IL-8 in human monocytes [5, 6], and ODN enhances the LPS-induced secretion of IL-6 in human peripheral blood mononuclear cells .
In human polymorphonuclear leukocytes (PMNs) we previously showed that TTN rises intracellular calcium ([Ca++]i) and stimulates chemotaxis, O2- generation, phagocytosis and IL-8 production [8, 9]. Pharmacological analysis of TTN-induced [Ca++]i changes and IL-8 production suggested that these responses are brought about through a pertussis toxin (PTX) sensitive, G protein-coupled receptor linked to phospholipase C (PLC), which once activated induces both Ca++ release from thapsigargine-sensitive intracellular stores and Ca++ entry from the extracellular space . In those experiments, preliminary evidence also suggested the possible involvement of protein kinase (PK) C, inasmuch as the PKC inhibitor calphostin C significantly affected (although did not completely block) TTN-induced effects.
The present study was therefore undertaken to investigate more in-depth, by use of a pharmacological approach, the role of PKC in the modulation of the response to TTN by human PMNs, and to better characterize TTN-induced Ca++ entry through the plasma membrane by testing its sensitivity to different Ca++-channel blockers. The results show that the stimulatory effect of TTN is profoundly affected by PKC activation, and suggest that different PKC isoforms may play distinct roles. Evidence is also provided that TTN-induced Ca++ entry is specifically sensitive to T-type Ca++-channel blockers. The possibility that T-type Ca++-channels may represent the target for the effects of these drugs on human PMNs is further supported by the observation that these cells express the mRNAs for T-type Ca++-channel α1 subunits.
Materials and Methods
Drugs and chemicals
TTN was obtained from Neosystem SA (Strasbourg, France); Bovine serum albumine (BSA), HEPES, EDTA, EGTA, Trizma Base, 12-O-tetradecanoylphorbol-13-acetate (PMA), 4α-phorbol-12,13-didecanoate (α-PMA), rottlerin, Ro 32-0432 (hydrochloride), L-verapamil, ω-conotoxin GVIA, flunarizine, and mibefradil (hydrochloride) were obtained from Sigma Aldrich (St. Louis, MO). Fura-2/AM was obtained from Calbiochem-Novabiochem Corp. (La Jolla, CA). Dextran and Ficoll-Paque Plus were obtained from Pharmacia Biotech (Uppsala, Sweden). All other reagents and solvents were from Merck (Darmstadt, Germany). All solutions were daily freshly preparated from stock solutions stored at -20°C until use.
PMNs were isolated from venous blood obtained from healthy volunteers using heparinized tubes. Whole blood was allowed to sediment on dextran at 37°C for 30 min. Supernatant was recovered and PMNs were isolated by Ficoll-Paque Plus density-gradient centrifugation. Contaminating erythrocytes were eliminated by 10 min hypotonic lysis in distilled water with added (g/l): NH4Cl 8.248, KHCO3 1.0, EDTA 0.037. Cells were then washed three times in NaCl 0.15 M and resuspended in 1 ml Ca++/Mg++-free PBS (composition as follows [g/l]: NaCl 8.000, KCl 0.200, Na2HPO4xH2O 1.288, KH2PO4 0.200) with added 0.25% BSA. Purity and viability of PMNs preparations were >95% and no platelets or erythrocytes could be detected either by light microscopic examination or by flow cytometric analysis.
Measurement of [Ca++]i
PMNs were resuspended at the concentration of 2 × 106/ml and incubated at 37°C with 5 μM Fura-2/AM (stock solution, 1 mM in dimethyl sulfoxide). After 30 min, cells were washed thrice by gentle centrifugation (5 min, 300 g), resuspended in PBS supplemented with 10 mM HEPES, 10 mM glucose, 0.25% BSA and 1 mM CaCl2 and placed in a thermostatically controlled (37°C) cuvette equipped with a cuvette stirrer for [Ca++]i measurement. Fluorescence measurements were performed using a spectrofluorimeter (Perkin-Elmer LS-50B, Perkin Elmer Instruments, Bridgeport, CT). Excitation of Fura-2 was performed at 340 and 380 nm, with excitation band widths set at 5 nm. The ratio of emitted fluorescence signals (510 nm) was used to calculate the cytosolic free Ca++ concentration according to Grynkiewicz et al.  and calibration was performed by the addition of 0.5% Triton X 100 and 1 mM CaCl2 (max) or 45 mM TRIS and 50 mM EGTA/TRIS (min). In each experiment, [Ca++]i changes were calculated as the difference (Δ) between the highest values (peak levels) reached after addition of the agent and the mean 1-min pretreatment values (resting levels).
PCR primers used for the detection of IL-8 and of T-type Ca++-channel α1 subunits.
Genbank n. M26434
Genbank n. AJ005353
Data are shown as means ± standard deviation (SD) of the mean. Statistical significance of the differences among groups was assessed by two-tailed Student's t test or by ANOVA followed by Bonferroni post test for paired or unpaired data, as appropriate. The concentration-response relationship of PMA was analyzed by nonlinear regression using a commercial software (Prism 2.0, GraphPad Software Inc., San Diego, CA, USA) and a sigmoidal concentration-response curve was fitted to find the mean value of the EC50 (i.e., the concentration which elicited 50% of the maximal response) together with its 95% confidence interval (C.I.).
Effect of PKC ligands
Effect of rottlerin and of Ro 32-0432 on PMA-dependent inhibition of the [Ca++]i rise induced by TTN. Data are expressed as percentage of the effect of TTN alone, and are shown as the mean ± SD of at least 3 separate experiments. * = P < 0.05, ** = P < 0.01 vs TTN alone; # = P < 0.01 vs TTN + PMA.
TTN 100 μM
100.0 ± 15.5
TTN 100 μM + PMA 1 ng/ml
29.3 ± 15.5**
TTN 100 μM + PMA 1 ng/ml
+ rottlerin 3 μM
25.0 ± 18.3**
+ rottlerin 5 μM
47.4 ± 15.1*
+ rottlerin 10 μM
61.5 ± 14.2*
TTN 100 μM + PMA 1 ng/ml
+ Ro 32-0432 5 nM
60.0 ± 13.2**
+ Ro 32-0432 20 nM
89.5 ± 14.7#
+ Ro 32-0432 50 nM
102.3 ± 15.1#
Effect of Ca++ channel blockers and evidence for the presence of T-type Ca++ channels in human PMNs
In our experiments, the PKC activator PMA prevented both TTN-induced [Ca++]i rise and IL-8 mRNA expression. Involvement of PKC was confirmed by the low EC50 value of PMA, by the inactivity of its negative control α-PMA, as well by the ability of two chemically unrelated PKC inhibitors such as Ro 32-0432 and rottlerin to revert this response. These observations stand for the existence of a PKC-operated inhibition of TTN-dependent pathways, a finding in line with the notion that in PMNs activation of PKC inhibits the signals responsible for mobilization of [Ca++]i . Interestingly however PMA did not completely prevent TTN-induced [Ca++]i rise, and a residual effect of the peptide (around 20% of the maximal effect) was still evident even in the presence of high concentrations of PMA (see Fig. 1). This is in line with our previous results showing that the PKC inhibitor calphostin C per se significantly reduced the effects of TTN in human PMNs, suggesting that activation of PKC was also part of the signaling process triggered by this peptide in PMNs .
PKC consists of a family of at least 12 serine/threonine kinases, which are currently divided into three main groups based on their structure and substrate requirements, namely: conventional (Ca++-dependent and activated by both phosphatidylserine [PS] and diacylglycerol [DAG], represented by α, βI, βII, and γ), novel (Ca++-independent and regulated by PS and DAG, represented by δ, ε, η, and θ), and atypical (Ca++-independent and regulated by PS but not by DAG, represented by ζ and ι/λ) . Recent studies have investigated the expression and role of PKC isoforms in human PMNs, showing in these cells the presence of conventional (βI, βII, and α, although in lower amounts), as well as novel (δ) PKC , and that different isoforms subserve distinct functions: conventional isoforms regulate PMA-stimulated cytoskeletal association and activation of NADPH oxidase, while novel isoforms modulate other responses that involve cytoskeletal components .
In our experiments, we have used the phorbol ester compound PMA, which penetrates the cytoplasmic membrane to directly bind and activate PKC . PMA however does not show a high degree of selectivity for PKC isoforms, thus resulting in activation of all PKC in the cell. In the present study, we have therefore investigated the ability of the PKC inhibitors Ro 32-0432 and rottlerin to revert the effect of PMA on TTN-induced [Ca++]i rise, as well as to affect per se this response. Rottlerin has been shown to inhibit PKCδ with some selectivity over other PKC isoforms, while Ro 32-0432 is selective for conventional isoforms (reviewed in ). According to our results, both drugs resulted in the reversion of PMA-induced inhibition of TTN-induced [Ca++]i rise (Table 2), however only rottlerin also inhibited per se the effect of TTN (Fig. 2). The EC50 of rottlerin in this regard was 5.77 μM, which is in good agreement with the reported IC50 for PKCδ (3–6 μM) . On the contrary, Ro 32-0432 in the 5–50 nM concentration range (which has been reported to be selective for conventional PKC isoforms ) had no effect per se on the response of human PMNs to TTN (Fig. 2). These findings, together with the observation that at variance with Ro 32-0432, rottlerin was only partially effective in reverting the effect of PMA (Table 2), may suggest that different isoforms of the enzyme play distinct roles in modulating the responses to TTN. While PKCδ seems to contribute to the rise of [Ca++]i induced by TTN, activation of conventional PKC isoforms (possibly, βI, βII, and/or α) may inhibit this response. When all the PKC isoforms undergo activation, as in the case of treatment with PMA, inhibition prevails over facilitation. In future studies, this hypothesis will be tested by investigating the pattern of activation of different PKC isoforms occurring as a result of TTN stimulation in human PMNs.
Few evidence exists about the possible contribution of membrane Ca++ channels to the effects of TTN on [Ca++]i. In rat astrocytes, TTN increases [Ca++]i through a peripheral-type benzodiazepine receptor-mediated opening of Ca++ channels which are sensitive to the L-type channel blocker nifedipine but not to the T-type channel blocker mibefradil nor to the N-type channel blocker ω-conotoxin GVIA , while in the frog adrenal gland, TTN-induced [Ca++]i rise involves the activation of membrane receptors positively coupled to adenylyl cyclase through a cholera toxin-sensitive G protein, which in turn results in Ca++ influx which is inhibited by mibefradil but not by nifedipine or ω-conotoxin GVIA . In our experiments, TTN-evoked [Ca++]i rise was significantly reduced by mibefradil and also by flunarizine, another T-type Ca++ channel blocker structurally different from mibefradil, whereas nifedipine, verapamil (another L-type channel blocker) and ω-conotoxin GVIA had no effect. Interestingly, the effect of TTN on [Ca++]i was not completely blocked, an evidence consistent with the idea that TTN increases [Ca++]i through both release from intracellular stores and entry through the plasma membrane .
The sensitivity of TTN-induced [Ca++]i rise to T-type channel blockers led us to investigate the expression of T-type Ca++ channels in human PMNs. Molecular studies have identified at least 3 voltage-gated Ca++ channel α1 subunits which share the biophysical and pharmacological properties of T-type channels, namely α1G, α1H, and α1I . In the present study, northern blot analysis provided evidence for the expression of the mRNA for all these 3 α1 subunits in human PMNs (Fig. 4). We are not aware of other studies showing the expression of T-type Ca++ channels in human PMNs, either at the level of mRNA or of the protein subunits, and the present findings may therefore represent the first evidence that such channels are expressed by these cells. Nonetheless, whether true voltage-dependent T-type Ca++ channels occur and play a relevant role in human PMNs remains still largely to be established. Electrophysiological studies of Ca++ influx in non-excitable cells such as leukocytes, including PMNs, have provided evidence for the existence of receptor-mediated, non voltage-operated Ca++ entry in these cells . Interesting observations however regard the possible occurrence, at least in lymphocytes, of non-voltage-operated Ca++ channels, with an amino acid sequence which is closely related to classical voltage-operated Ca++ channels (reviewed in ). In human PMNs flunarizine has been shown to inhibit Ca++ entry triggered by fMLP or by the Ca++ ionophore A23187 . Available data, including those reported in the present study, seem thus to support the existence in human PMNs of Ca++ entry mechanisms which are closely related to T-type Ca++ channels, from both the structural and the pharmacological point of view. Such mechanisms are likely to be involved in the response of human PMNs to TTN, and may represent the target of T-type channel blockers such as flunarizine and mibefradil.
In conclusion, the present results together with previous studies [8, 9] suggest that in human PMNs the endozepine TTN activates G protein-coupled membrane receptors, resulting in a signaling cascade which comprises PLC and PKC. This latter enzyme in particular may exert both positive and negative effects on TTN signaling, possibly depending on the specific isoform(s) involved. TTN-activated pathways finally result in increased [Ca++]i, due to both Ca++ release from intracellular stores and Ca++ entry possibly through T-type Ca++ channels. [Ca++]i rise then signals for activation of cell function, including mRNA expression and release of the chemokine IL-8 (Fig. 5). DBI is released from nerve terminals and its fragments can be detected in liquor and peripheral blood . Endozepines such as TTN may therefore contribute to the central nervous system-immune system cross-talk. In addition DBI, also called acyl-CoA binding protein, is widely distributed in many peripheral organs such as gut and endocrine cells of the pancreatic islets [23, 24], liver, kidney , adrenals , adipose tissue, heart, muscles and mammary gland  of different species, and in circulating mononuclear cells , in red blood cells  and even in neoplastic cell lines . High concentrations of DBI and/or of its processing products may therefore occur locally, e.g. as the result of leakage from damaged cells during tissue injury. DBI-derived peptides may thus also add to the multiple agents constituting the local microenvironment in inflamed tissues. Studies are therefore warranted to develop TTN-receptor ligands to assess the relevance of TTN-operated pathways as novel targets for the pharmacological modulation of PMNs during the inflammatory process.
The Authors are grateful to Prof. Giovanni Chelazzi and Dr. Davide Rossi, Immunohematology and Transfusional Service, Ospedale di Circolo, Varese, Italy, who collaborated in providing human blood.
- Rose TM, Schultz ER, Todaro GJ: Molecular cloning of the gene for the yeast homolog (ACB) of diazepam binding inhibitor/endozepine/acyl-CoA-binding protein. Proc Natl Acad Sci USA. 1992, 89: 11287-11291.PubMed CentralView ArticlePubMedGoogle Scholar
- Alho H, Fremeau RT, Tiedge H, Wilcox J, Bovolin P, Brosius J, Roberts JL, Costa E: Diazepam-binding inhibitor gene expression: location in brain and peripheral tissues of rat. Proc Natl Acad Sci USA. 1988, 85: 7018-7022.PubMed CentralView ArticlePubMedGoogle Scholar
- Tonon MC, Desy L, Nicolas P, Vaudry H, Pelletier G: Immunocytochemical localization of the endogenous benzodiazepine ligand octaneuropeptide (ODN) in the rat brain. Neuropeptides. 1990, 15: 17-24. 10.1016/0143-4179(90)90155-R.View ArticlePubMedGoogle Scholar
- Bovolin P, Schlichtin JL, Miyata M, Ferrarese C, Guidotti A, Alho H: Distribution and characterization of diazepam binding inhibitor (DBI) in peripheral tissues of rat. Regul Peptides. 1990, 29: 267-281. 10.1016/0167-0115(90)90089-F.View ArticleGoogle Scholar
- Taupin V, Herbelin A, Descamps-Latscha B, Zavala F: Endogenous anxiogenic peptide, ODN-diazepam-binding inhibitor, and benzodiazepines enhance the production of interleukin-1 and tumor necrosis factor by human monocytes. Lymphokine Cytokine Res. 1991, 10: 7-13.PubMedGoogle Scholar
- Taupin V, Gogusev J, Descamps-Latscha B, Zavala F: Modulation of tumor necrosis factor-α, interleukin-1β, interleukin-6, interleukin-8, and granulocyte/macrophage colony-stimulating factor expression in human monocytes by an endogenous anxiogenic benzodiazepine ligand, triakontatetraneuropeptide: evidence for a role of prostaglandins. Mol Pharmacol. 1993, 43: 64-69.PubMedGoogle Scholar
- Stepien H, Agro A, Crossley J, Padol I, Richards C, Stanisz A: Immunomodulatory properties of diazepam-binding inhibitor: effect on human interleukin-6 secretion, lymphocyte proliferation and natural killer cell activity in vitro. Neuropeptides. 1993, 25: 207-211. 10.1016/0143-4179(93)90104-I.View ArticlePubMedGoogle Scholar
- Cosentino M, Marino F, Cattaneo S, Di Grazia L, Francioli C, Fietta AM, Lecchini S, Frigo GM: Diazepam-binding inhibitor-derived peptides induce intracellular calcium changes and modulate human neutrophil function. J Leukoc Biol. 2000, 67: 637-643.PubMedGoogle Scholar
- Marino F, Cosentino M, Fietta AM, Ferrari M, Cattaneo S, Frigo G, Lecchini S, Frigo GM: Interleukin-8 production induced by the endozepine triakontatetraneuropeptide in human neuteophils: role of calcium and pharmacological investigation of signal transduction pathways. Cell Signal. 2003, 15: 511-517. 10.1016/S0898-6568(02)00134-1.View ArticlePubMedGoogle Scholar
- Grynkiewicz G, Poenie M, Tsien RY: A new generation of calcium indicators with greatly improved fluorescence properties. J Biol Chem. 1985, 260: 3440-3450.PubMedGoogle Scholar
- Naccache PH, Molski TFP, Borgeat P, White JR, Sha'afi RI: Phorbol esters inhibit the fMet-Leu-Phe- and leukotriene B4-stimulated calcium mobilization and enzyme secretion in rabbit neutrophils. J Biol Chem. 1985, 260: 2125-2131.PubMedGoogle Scholar
- Way KJ, Chou E, King GL: Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol Sci. 2000, 21: 181-187. 10.1016/S0165-6147(00)01468-1.View ArticlePubMedGoogle Scholar
- Balasubramanian N, Advani SH, Zingde SM: Protein kinase C isoforms in normal and leukemic neutrophils: alterde levels in leukemic neutrophils and changes during myeloid maturation in chronic myeloid leukemia. Leuk Res. 2002, 26: 67-81. 10.1016/S0145-2126(01)00098-4.View ArticlePubMedGoogle Scholar
- Nixon JB, McPhail LC: Protein kinase C (PKC) isoforms translocate to triton-insoluble fractions in stimulated human neutrophils: Correlation of conventional PKC with activation of NADPH oxidase. J Immunol. 1999, 163: 4574-4582.PubMedGoogle Scholar
- Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y: Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor promoting phorbol esters. J Biol Chem. 1982, 257: 7847-7851.PubMedGoogle Scholar
- Gandolfo P, Louiset E, Patte C, Leprince J, Masmoudi O, Malagon M, Gracia-Navarro F, Vaudry H, Tonon MC: The triakontatetraneuropetide TTN increases [Ca2+]i in rat astrocytes through activation of peripheral-type benzodiazepine receptors. Glia. 2001, 35: 90-100. 10.1002/glia.1074.View ArticlePubMedGoogle Scholar
- Lesouhaitier O, Kodjio MK, Cartier F, Contesse V, Yon L, Delarue C, Vaudry H: The effect of the endozepine triakontatetraneuropeptide on corticosteroid secretion by the frog adrenal gland is mediated by action of adenylyl cyclase and calcium influx trough T-type calcium channels. Endocrinology. 2000, 141: 197-207. 10.1210/en.141.1.197.PubMedGoogle Scholar
- Perez-Reyes E: Molecular physiology of low-voltage-activated T-type clacium channels. Physiol Rev. 2003, 83: 117-161.View ArticlePubMedGoogle Scholar
- Li SL, Westwick J, Poll CT: Receptor-operated Ca2+ influx chennels in leukocytes: a therapeutic target?. Trends Pharmacol Sci. 2002, 23: 63-70. 10.1016/S0165-6147(00)01897-6.View ArticlePubMedGoogle Scholar
- Grafton G, Thwaite L: Calcium channels in lymphocytes. Immunology. 2001, 104: 119-126. 10.1046/j.0019-2805.2001.01321.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Laghi Pasini F, Capecchi PL, Pasqui AL, Ceccatelli L, Mazza S, Gistri A, Di Perri T: Adenosine system and cell calcium translocation. Interference of calcium channel blockers. Exp Gerontol. 1990, 25: 383-391. 10.1016/0531-5565(90)90076-E.View ArticlePubMedGoogle Scholar
- Ferrarese C, Vaccarino F, Alho H, Mellstrom B, Costa E, Guidotti A: Subcellular location and neuronal release of diazepam binding inhibitor. J Neurochem. 1987, 48: 1093-1102.View ArticlePubMedGoogle Scholar
- Ostenson CG, Ahren B, Johansson O, Karlsson S, Hilliges M, Efendic S: Diazepam binding inhibitor and the endocrine pancreas. Neuropharmacology. 1991, 30: 1391-1398.View ArticlePubMedGoogle Scholar
- Gossett RE, Schroeder F, Gunn JM, Kier AB: Expression of fatty acyl-CoA binding proteins in colon cells: response to butyrate and transformation. Lipids. 1997, 32: 577-585.View ArticlePubMedGoogle Scholar
- Owens GP, Sinha AK, Sikela JM, Hahn WE: Sequence and expression of the murine diazepam binding inhibitor. Mol Brain Res. 1989, 6: 101-108. 10.1016/0169-328X(89)90043-0.View ArticlePubMedGoogle Scholar
- Besman MJ, Yanagibashi K, Lee TD, Kawamura M, Hall PF, Shively JE: Identification of des-(Gly-Ile)-endozepine as an effector of corticotropin-dependent adrenal steroidogenesis: Stimulation of cholesterol delivery is mediated by the peripheral benzodiazepine receptor. Proc Natl Acad Sci USA. 1989, 86: 4897-4901.PubMed CentralView ArticlePubMedGoogle Scholar
- Mikkelsen J, Knudsen J: Acyl-CoA-binding protein from cow. Binding characteristics and cellular and tissue distribution. Biochem J. 1987, 248: 709-714.PubMed CentralView ArticlePubMedGoogle Scholar
- Rocca P, Belloni G, Benna P, Bergamasco B, Ravizza L, Ferrero P: Peripheral-type benzodiazepine receptors and diazepam binding inhibitor-like immunoreactivity distribution in human peripheral blood mononuclear cells. Immunopharmacology. 1993, 25: 163-178. 10.1016/0162-3109(93)90018-L.View ArticlePubMedGoogle Scholar
- Fyrst H, Knudsen J, Schott MA, Lubin BH, Kuypers FA: Detection of acyl-CoA-binding protein in human red blood cells and investigation of its role in membrane phospholipid renewal. Biochem J. 1995, 306: 793-799.PubMed CentralView ArticlePubMedGoogle Scholar
- Swinnen JV, Esquenet M, Rosseels J, Claessens F, Rombauts W, Heyns W, Verhoeven G: A human gene encoding diazepam-binding inhibitor/acyl-CoA-binding protein: transcription and hormonal regulation in the androgen-sensitive human prostatic adenocarcinoma cell line LNCaP. DNA & Cell Biol. 1996, 15: 197-208.View ArticleGoogle Scholar
- Siddiqui RA, Akard LP, Garcia JGN, Cui Y, English D: Chemotactic migration triggers IL-8 generation in neutrophilic leukocytes. J Immunol. 1999, 162: 1077-1083.PubMedGoogle Scholar
- Hirooka K, Bertolesi GE, Kelly MEM, Denovan-Wright EM, Sun X, Hamid J, Zamponi GW, Juhasz AE, Haynes LW, Barnes S: T-type calcium channel α1F and α1H subunits in human retinoblastoma cells and their loss after differentiation. J Neurophysiol. 2002, 88: 196-205.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.